Last reviewed · How we verify
escitalopram and tramadol
escitalopram and tramadol is a SSRI + opioid analgesic combination Small molecule drug developed by University of Southern Denmark. It is currently FDA-approved for Depression with concurrent pain conditions, Major depressive disorder with chronic pain. Also known as: Lexapro, Ultram.
This combination pairs a selective serotonin reuptake inhibitor (escitalopram) with an opioid analgesic and norepinephrine reuptake inhibitor (tramadol) to treat depression and pain conditions.
This combination pairs a selective serotonin reuptake inhibitor (escitalopram) with an opioid analgesic and norepinephrine reuptake inhibitor (tramadol) to treat depression and pain conditions. Used for Depression with concurrent pain conditions, Major depressive disorder with chronic pain.
At a glance
| Generic name | escitalopram and tramadol |
|---|---|
| Also known as | Lexapro, Ultram |
| Sponsor | University of Southern Denmark |
| Drug class | SSRI + opioid analgesic combination |
| Target | Serotonin transporter (SERT), norepinephrine transporter (NET), mu-opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Pain Management |
| Phase | FDA-approved |
Mechanism of action
Escitalopram increases serotonin availability in the brain by blocking its reuptake at the synaptic cleft, addressing depressive symptoms. Tramadol acts as a weak mu-opioid receptor agonist and inhibits reuptake of norepinephrine and serotonin, providing analgesic effects. The combination targets both mood and pain pathways, though concurrent use carries risk of serotonin syndrome due to additive serotonergic effects.
Approved indications
- Depression with concurrent pain conditions
- Major depressive disorder with chronic pain
Common side effects
- Nausea
- Dizziness
- Headache
- Constipation
- Serotonin syndrome
- Seizures
- Somnolence
Key clinical trials
- Implementation of Personalized Medicine for Optimal Drug Therapy in Cancer
- A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program (NA)
- Evaluation of Stepped Care for Chronic Pain in Iraq/Afghanistan Veterans (ESCAPE) (NA)
- YouScript IMPACT Registry
- The Effect of Escitalopram on the Pharmacokinetics and Pharmacodynamics of Tramadol in Healthy Subjects (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- escitalopram and tramadol CI brief — competitive landscape report
- escitalopram and tramadol updates RSS · CI watch RSS
- University of Southern Denmark portfolio CI
Frequently asked questions about escitalopram and tramadol
What is escitalopram and tramadol?
How does escitalopram and tramadol work?
What is escitalopram and tramadol used for?
Who makes escitalopram and tramadol?
Is escitalopram and tramadol also known as anything else?
What drug class is escitalopram and tramadol in?
What development phase is escitalopram and tramadol in?
What are the side effects of escitalopram and tramadol?
What does escitalopram and tramadol target?
Related
- Drug class: All SSRI + opioid analgesic combination drugs
- Target: All drugs targeting Serotonin transporter (SERT), norepinephrine transporter (NET), mu-opioid receptor
- Manufacturer: University of Southern Denmark — full pipeline
- Therapeutic area: All drugs in Psychiatry / Pain Management
- Indication: Drugs for Depression with concurrent pain conditions
- Indication: Drugs for Major depressive disorder with chronic pain
- Also known as: Lexapro, Ultram
- Compare: escitalopram and tramadol vs similar drugs
- Pricing: escitalopram and tramadol cost, discount & access